Please use this identifier to cite or link to this item:
|Title:||Current status of positron emission tomography in oncology.|
|Authors:||Scott, Andrew M|
|Affiliation:||Centre for Positron Emission Tomography, Austin & Repatriation Medical Centre and Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia.|
|Citation:||Australasian Radiology; 46(2): 154-62|
|Abstract:||Positron emission tomography (PET) has emerged as a powerful diagnostic tool in oncology patients. There is evidence of the superior utility over conventional imaging methods of the principal PET tracer 18F-fluoro-2-deoxy-glucose in the staging of a range of cancers and monitoring disease recurrence, as well as changing patient management to more appropriate therapy. The methods for evaluating the evidence for PET remain complex, particularly as the standard evidence-based approach of randomized controlled trials is not generally applicable to imaging technologies. PET has the potential to dramatically improve our ability to manage patients with cancer and is also making major contributions to the development of new therapies.|
|Internal ID Number:||12060153|
Fluorodeoxyglucose F18.diagnostic use
Neoplasm Metastasis.radionuclide imaging
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.